The estimated Net Worth of Austin D. Kim is at least $2.77 millió dollars as of 6 January 2024. Mr. Kim owns over 1,634 units of Acadia Pharmaceuticals Inc stock worth over $757,481 and over the last 6 years he sold ACAD stock worth over $106,635. In addition, he makes $1,906,130 as Executive Vice President, General Counsel és and Secretary at Acadia Pharmaceuticals Inc.
Austin has made over 15 trades of the Acadia Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,634 units of ACAD stock worth $26,062 on 6 January 2024.
The largest trade he's ever made was exercising 36,174 units of Acadia Pharmaceuticals Inc stock on 5 October 2023 worth over $576,975. On average, Austin trades about 4,394 units every 71 days since 2018. As of 6 January 2024 he still owns at least 47,491 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kim stock trades at the bottom of the page.
Austin D. Kim is Executive Vice President, General Counsel, and Secretary of the Company. He is our Executive Vice President, General Counsel, and Secretary and has been with our company since July 2018. From 2006 until 2017, Mr. Kim held several senior legal positions at Teva Pharmaceuticals, a global specialty pharmaceutical company. At Teva, Mr. Kim was most recently Vice President and Deputy General Counsel, Corporate/M&A, handling corporate and securities law matters, acquisitions and corporate development, capital markets transactions and corporate governance matters. Before joining Teva, Mr. Kim was Deputy General Counsel at IVAX Corporation, a global generic pharmaceutical company, which was acquired by Teva in 2006. Earlier in his career, Mr. Kim was a senior lawyer at Transamerica Corporation, practiced law at Pillsbury, Madison & Sutro and clerked for Judge Vaughn Walker of the United States District Court, Northern District of California. Mr. Kim received his J.D. from Columbia University School of Law and his A.B. in English literature and economics from Stanford University.
As the Executive Vice President, General Counsel és and Secretary of Acadia Pharmaceuticals Inc, the total compensation of Austin Kim at Acadia Pharmaceuticals Inc is $1,906,130. There are 4 executives at Acadia Pharmaceuticals Inc getting paid more, with Stephen Davis having the highest compensation of $7,631,250.
Austin Kim is 56, he's been the Executive Vice President, General Counsel és and Secretary of Acadia Pharmaceuticals Inc since 2018. There are 10 older and 6 younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
Austin's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... és Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: